Wockhardt snags Covid-19 vaccine manufacturing deal from the UK govt

This deal by Wockhardt entails only manufacturing the vaccine only for the United Kingdom. The government has reserved one fill and finish production line for its exclusive use for the next 18 months in order to guarantee the supply of vaccines re...

MUMBAI: Shares of Mumbai based Wockhardt pharma jumped by 10% on close of Monday's trade after the company announced that its UK subsidiary will be manufacturing the AstraZeneca-Oxford University Covid-19 vaccines for the UK government. As part of the agreement the company has reserved its manufacturing capacity to supply multiple vaccines to the UK government. The manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales. Shares of the company closed at Rs 303.

The amount of the deal was not disclosed.

This deal by Wockhardt entails only manufacturing the vaccine only for the United Kingdom. The government has reserved one fill and finish production line for its exclusive use for the next 18 months in order to guarantee the supply of vaccines required to fight COVID-19 in the UK, Wockhardt said in a statement.


“We have a sophisticated sterile manufacturing facility and a highly skilled workforce. We expect to start delivering the first doses of the vaccine later this year.” said Ravi Limaye, MD, Wockhardt UK.

Kate Bingham, Chair of U.K. Vaccines Task Force said that discovering a successful vaccine is only part of the solution, but we also need to be able to manufacture it. "Fill Finish is a critical step in the process to get the vaccine in a form to be given to patients. The agreement with Wockhardt will boost our capability to ensure that from the moment a successful vaccine is identified we will be able to produce the quantities of vaccine required, as quickly as possible, for the people who need it,” Bingam said.

With this deal the UK has managed to secure additional capacity to manufacture millions of doses of multiple Covid-19 candidates.
ADVERTISEMENT

In India AstraZeneca has tied up with Serum Institute of India to manufacture 400 mn doses for India by the end of this year. Wockhardt in the UK is one of the largest suppliers into the National Health System.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

Related Companies

More from our Partners

Loading next story
Text Size:AAA
Success
This article has been saved

*

+